Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

54.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.4K
What is Cancer?02:12

What is Cancer?

14.5K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.5K
Cancer Prevention02:59

Cancer Prevention

8.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.1K
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Skin Cancer01:30

Skin Cancer

5.9K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

Metastasis-directed Therapy in Oligometastatic Castration-resistant Prostate Cancer: From Chasing the Last Metastasis to Changing the Game?

International journal of radiation oncology, biology, physics·2026
Same author

Correlation of Biochemical Recurrence With Adverse Late Toxic Events Following Prostate Radiation Therapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

International journal of radiation oncology, biology, physics·2026
Same author

In Reply to Harnett.

International journal of radiation oncology, biology, physics·2025
Same author

In Reply to Starrs et al.

International journal of radiation oncology, biology, physics·2025
Same author

In Regard to Skubish et al.

Practical radiation oncology·2025

Related Experiment Video

Updated: Feb 7, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K

Moderate hypofractionation for prostate cancer.

W Robert Lee1, Bridget F Koontz1

  • 1Department of Radiation Oncology, Duke University School of Medicine, Durham, NC 27710, USA.

Translational Andrology and Urology
|July 28, 2018
PubMed
Summary
This summary is machine-generated.

Moderate hypofractionation (HF) in prostate cancer radiation therapy shows comparable efficacy to conventional fractionation (CF), offering potential logistic and financial benefits. Evidence from randomized trials supports HF as a viable treatment option.

Keywords:
Hypofractionation (HF)prostate cancerradiotherapy

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K

Related Experiment Videos

Last Updated: Feb 7, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.6K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • The study of radiation fractionation in cancer treatment spans over a century.
  • A 1999 report highlighted hypofractionated regimens for prostate cancer, suggesting therapeutic and logistical advantages.
  • Accumulating evidence over two decades addresses the efficacy and toxicity of hypofractionation in prostate cancer radiotherapy.

Purpose of the Study:

  • To review and analyze randomized trials comparing moderate hypofractionation (HF) with conventional fractionation (CF) for prostate cancer treatment.
  • To evaluate the therapeutic ratio, efficacy, and toxicity of moderate HF regimens.

Main Methods:

  • Focus on randomized trials comparing moderate hypofractionation (HF) to conventional fractionation (CF).
  • Exclusion of extreme hypofractionation, which is addressed in a separate review.
  • Synthesis of medical evidence, both strong and weak, on efficacy and toxicity.

Main Results:

  • Moderate hypofractionation (HF) demonstrates comparable efficacy to conventional fractionation (CF) in prostate cancer treatment.
  • Evidence suggests potential logistic and financial advantages associated with HF regimens.
  • The review synthesizes data on the efficacy and toxicity profiles of moderate HF.

Conclusions:

  • Moderate hypofractionation is a viable radiotherapy option for prostate cancer, offering similar outcomes to conventional fractionation.
  • The adoption of moderate HF may present logistical and financial benefits in clinical practice.
  • Further evidence supports the role of moderate hypofractionation in the evolving landscape of prostate cancer management.